Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
Table 1
Characteristics of nonresponders to interferon-free therapy retreated with genotype specific DAA regimens, compared to the whole population of patients included in the EpiTer-2 database.
Parameter
Studied population
n=31
females/males, n (%)
16/15 (52%/48%)
Age [years], mean ± SD; min-max
54 ± 11; 23-77
HCV genotype, n (%)
1b
23 (74%)
3
3 (10%)
4
5 (16%)
Fibrosis, n (%)
F0
1 (3%)
F1
3 (10%)
F2
3 (10%)
F3
2 (6%)
F4
22 (71%)
Primary regimen, on schedule/discontinued, n (%)
19/12 (61%/39%)
OBV/PTV/r+DSV ± RBV, on schedule
4 (13%)
OBV/PTV/r+DSV ± RBV, discontinued
11 (35%)
LDV/SOF ± RBV, on schedule
7 (23%)
LDV/SOF ± RBV, discontinued
0
ASV+DCV, on schedule
3 (10%)
ASV+DCV, discontinued
1 (3%)
SOF+RBV, on schedule
3 (10%)
SOF+RBV, discontinued
0
Other SOF based†, on schedule
2 (6%)
Other SOF based†, discontinued
0
History of primary regimen failure, n (%)
Discontinued due to adverse events
11 (35%)
Relapse
10 (32%)
Non-response
9 (29%)
Other‡
1 (3%)
Period between primary and rescue therapy [months], mean ± SD; min-max
9.0 ± 5.0; 0-18
†SOF+SMV+RBV and SOF+DCV+RBV. ‡improper primary regimen discontinued after 4 weeks. DAA: direct acting antivirals; SD: standard deviation; HCV: hepatitis C virus; F: fibrosis; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir; SMV: simeprevir.